Curcuma longa commonly known as turmeric has been used in Indian Ayurvedic medicine as a constituent to treat various disorders. It is by now clear that principal curcuminoid of turmeric; curcumin, a yellow pigment, is responsible for these beneficiary activities. The aim of the present study was to evaluate anti-mycobacterial effect of curcumin (CMN) on intracellular growth of MDR clinical isolates of Mycobacterium tuberculosis (MTB). Curcumin was evaluated for its efficacy to inhibit the intracellular growth of MTB H37Rv and two MDR clinical isolates in Raw 264.7 cell line using CFU assay. Resazurin microtiter plate assay (REMA) was used to evaluate its direct anti-mycobacterial activity.
INTRODUCTION

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB)
, is a public-health problem worldwide with a global mortality of 1.4 million with 350,000 deaths each year in India [1, 2] . The situation is further exacerbated with increasing incidence of multi-drug resistant (MDR), extensively drug resistant (XDR) TB and co-infection of HIV.
Current drug regimens are far from effectively controling the incidence of drug resistance of MTB. Hence, the discovery of novel agents targeting host rather than pathogen is need of hour [3] . Since, MTB is known to alter signaling required for the production of immunostimulatory cytokines and effectors molecules in the host [4] , immunomodulation beneficial to host, appears a viable strategy to control the pathogen.
Curcumin (CMN-[diferuloylmethane or 1,7-bis (4-hydroxy-3-methoxy-phenyl) hepta-1, 6-diene-3, 5-dione)]) is a yellow pigment from the rhizomes of perennial herb Curcuma longa commonly known as turmeric. It has been shown to modulate various molecular targets in malignancy and signaling cascades involved in both innate and acquired immune response and, hence is utilized to treat various disorders including arthritis, cardiovascular disorders, cancers, and other pathologies [5] . In addition, CMN and largely its analogs have exhibited the antimicrobial and anti-mycobacterial activity in nonpathogenic species [6] .
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The aim of the present study was to evaluate antimycobacterial efficiency of CMN on intracellular growth of MDR clinical isolates of MTB inside RAW 264.7 cells at lower doses.
MATERIALS& METHODS
Reagents
Curcumin, resazurin sodium salt and MTT were obtained from Sigma Aldrich. Cell culture media DMEM and fetal calf serum were purchased from Gibco, Life Technologies. Bacterial culture media Middlebrook 7H9, 7H11, ADC and OADC were purchased from Difco, BD biosciences. LJ tubes containing antibiotics were purchased from EOS labs, Mumbai.
Bacterial Cultures and Cell Lines
M. tuberculosis clinical isolates strain-1 and strain-2 were recovered from patients in Tata memorial hospital, and KEM hospital, Mumbai (INDIA). The laboratory strain H37Rv was also included in the study. All M. tuberculosis strains were grown in Middlebrook 7H9 medium supplemented with ADC (albumin-dextrose complex), and containing 0.05% Tween 80 for 10 days 37°C with daily agitation; working stocks were prepared (10 8 bacilli/ml) stored at -70°C until use. All procedures were carried out in a Biosafety Level III (BSL III) laboratory. Murine macrophage cell line RAW 264.7 was obtained from NCCS Pune, India and maintained in DMEM at 37°C, in an atmosphere containing 5% CO2.
Drug Susceptibility Testing
Drug susceptibility of two clinical isolates to rifampicin, ethambutol, streptomycin, isoniazide, pyrazinamide, kanamycin, ethionamide clarithromycin, ciprofloxacin, cycloserine, amikacin, p-amino salicylic acid, rifabutin, was performed by standard proportion method [7] .
Resazurin Microtiter Plate Assay (REMA)
The risazurin plate assay was performed in Middlebrook 7H9 broth supplemented with ADC, as described [8] . Briefly, dilutions of CMN were prepared in 7H9 broth and 100µl of this was dispensed in sterile 96 well plates at concentrations of 5-50µM. Isoniazid was used as positive control. One hundred microliters of inoculum containing 10 4 MTB cells was added to each well. Periphery wells were filled with sterile water to minimize evaporation. The plate was covered, sealed with paraffin, and incubated a 37°C for 7 days. Thirty microliters of resazurin solution were added to each well, and the plate was incubated overnight. A change in color from blue to pink signified the growth of bacteria, and the lowest concentration of drug that prevented this change in color was defined as MIC.
Cell viability Assay
Effect of CMN treatment on viability of RAW 264.7 cell was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay as described [9] . Briefly, 5x10 3 RAW264.7 cells were seeded per well, in 96 well plates, kept in incubator at 37ºC, with 5% CO 2 overnight. Following day CMN was added at concentration from 2µM to 100µM and plates were incubated further for another 24 hours. MTT was added and after 3 hours incubation at 37ºC, lysis buffer was added (10% SDS, 25% dimethylformamide, pH 4.7). Twenty four hours later, absorbance was measured at 570 nm and 630 nm with a microtiter plate reader.
Macrophage Infection and CFU Assay
All MTB strains growing in Middlebrook 7H9 broth supplemented with ADC at mid-log growth phase were harvested. Single cell suspensions were prepared in DMEM medium after vortexing washed pellets with the glass beads, followed by repeated passage through 26G needle. RAW 264.7 cells were seeded at a density of 2 x10 5 cells/well and infected with MTB strains at an MOI of 5, for 3 hours. Cells were washed with pre-warmed media followed by treatment with amikacin (10 µg/ml) to kill the extracellular bacteria [10] . CMN was added at various concentrations (10 µM, 25 µM 50 µM) and cells were incubated for 48 and 96 hours. For CFU assay, infected cells were washed with PBS and lysed with 0.01% SDS containing PBS at different time points. Serial dilutions were prepared in PBS and plated on 7H11 medium supplemented with OADC.
Statistical Analysis
SigmaStat (version 3.5) was used for statistical analysis. Data were presented as mean ± standard deviation (P<0.05).
RESULTS
MDR Status of Strains
Drug sensitivity testing of both the clinical isolates demonstrated the multidrug resistant status of both isolates. Strain-1 exhibited resistance to 6 drugs and strain-2 showed resistance to 10 drugs ( Table 1) Cell Viability Assay Cytotoxicity of CMN on pathogen (MTB) and host cells (RAW 264.7) was evaluated independently by REMA and MTT assay respectively. REMA demonstrated the absence of direct anti-mycobacterial activity of CMN against MTB strains up to 50µM (18.41µg/ml). MTT assay showed that concentrations of CMN up to 100µM were non-toxic to RAW 264.7 cells (Fig. 1) .
Inhibition of Intracellular Survival of MTB Strains by Curcumin
There was a dose dependent inhibition of intracellular survival of MTB strains, when MTB infected macrophages were treated with the various doses (10 µM, 25 µM 50 µM) of CMN for 48 (Fig. 2, A) and 96 hours (Fig. 2, B) . Table 2 illustrates the values of percent inhibition of intracellular survival of MTB inside macrophages.
Percentage of inhibition of intracellular survival of MTB H37Rv after CMN treatment (10µM) was significantly higher than strain -2 (p<0.05) and strain -1 (p<0.001) at 48 hours post treatment. There was no significant difference observed among the percentage inhibition with all three strains at two higher doses (25µM, 50µM) at the same time point. Similarly, percent inhibition of intracellular survival of H37Rv after CMN (50µM) treatment is significantly higher than strain 2 (p<0.001) and strain 1 (p<0.05) after 96 hours. No significant difference was observed at 10 µM and 25 µM CMN treatment at 96 hours.
DISCUSSION
The rapid emergence of MDR and XDR TB, which is difficult to treat, is an issue of great concern; hence, now time has come to think about some novel therapeutic ap- proaches targeting the host immunity. It has been reported that use of TLR9 agonist (CpG oligonucleotides) partially inhibits the growth of intracellular MTB [11] . Further many immunomodulators are currently in clinical trial because of their anti-infective properties against various pathogens [12] . The aim of the present study was to evaluate the ability of CMN for the inhibition of intracellular survival of MTB in macrophages. Earlier reports demonstrated the direct antimycobacterial activity of CMN against non pathogenic MTB H37Ra at higher dose [6] (MIC: 100µg/ml), and nontuberculosis mycobacteria (e.g. M. kansasii, M simiae, M.smegmatis etc.) [13] but in the present study, lower dose (18.14µg/ml) of CMN has been used which does not exhibit any direct anti-mycobacterial property. The percent inhibition observed for of H37Rv was significantly higher than drug resistant strain-1 and strain-2, at 10µM and 25µM of CMN dose after 48 hours. This may be attributed to i) highly drug resistant status of two clinical isolates, and ii) differential host response evoked by these highly virulent strains. The mode of action of inhibition is dependent on the host response than the direct action on MTB. Our group has already reported that both clinical isolates belong to two different genetic lineages and have displayed differential innate immune responses in human monocytic cell line THP-1 [14] .
Interestingly percentage inhibition of intracellular survival of all the three strains at 96 hours of CMN treatment (10µM) was lower than the inhibition observed at 48 hours of CMN treatment. The degradation of CMN over the extended time period might have led to poor efficacy and thus decreased percent inhibition at this concentration. Though CMN did not exhibit any direct anti-mycobaterial effect up to 50 µM, the treatment of MTB infected macrophages with CMN resulted in dose dependent inhibition of intracellular growth of all the three strains under the study.
CMN is known to induce the expression of cathelicidin, an antimicrobial peptide in human monocytic cell line U-937 [15] and cathelicidin was independently shown to be involved in intracellular killing of MTB in murine macrophages [16] . We envisage that, the induction of antimicrobial peptides in MTB infected macrophages after CMN treatment may be a potential mode of action by which it inhibited the survival of MTB strains in macrophages.
Finally the absence of direct anti-mycobacterial effect of CMN indicates that inhibition of intracellular survival of MTB strains inside macrophages is probably the result of modulation of macrophage responses. This inhibition, unlike antibiotics, is achieved by targeting the host rather than the pathogen. This is a novel finding and similar reports on antimycobacterial effects of natural products are not available.
CONCLUSION
Rapid emergence of drug resistance in MTB strains even to newly discovered antibiotics is very alarming situation. Thus, in this era of MDR and XDR tuberculosis, conventional drug regimes are unable to control the pathogen and hence, in this scenario targeting the host rather than the pathogen to control tuberculosis, seems promising. Unlike antibiotics, this approach is not target specific and it involves the modulation of various host protective responses and hence, is by and large impervious to the development of drug resistance. In the present study, CMN did not show direct inhibitory action on MTB but inhibited the survival of MTB strains inside the macrophages, indicating the mode of action by targeting of host responses which is yet to be discovered. Here, we do not wish to propose CMN as a therapeutic candidate but we are only putting forward a proof of concept. Hence, detailed investigation of the responses and mechanism underlying may lay a foundation for this novel approach having potential to be used as adjuvant to the existing drug regime.
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